ESMO 2018 VL

STARTAR Trial: Systemic Therapy in Salvage Setting for Prostate Cancer- Tian Zhang

Details
(Length of Discussion: 8 min) Tian Zhang discusses with Alicia Morgans the STARTAR trial, a phase 2 enrolling high risk prostate cancer patients with Gleason 7 T3 or Gleason 8-10 who have developed PSA recurrence and adding systemic agents to standard of care with the goal of extending the lives of this patient population. They discuss logistics for patients who may qualify for this trial. Biograp...

Evolution of the NCCN Guidelines for Kidney Cancer -Tian Zhang

Details
(Length of Discussion: 12 min) Tian Zhang and Charles Ryan highlight recent updates in the NCCN treatment guidelines for kidney cancer resulting from data leading to changes in treatment options. Incorporation of initial diagnosis, disease biology, risk category, and clinical factors assist with selecting the most appropriate therapy for these patients. Biographies: Tian Zhang, MD, Assistant Profe...

A Conversation on Immuno-Oncology in Bladder Cancer - Petros Grivas

Details
(Length of Discussion: 12 min) A conversation between Petros Grivas and Alicia Morgans where they discuss the trials in the neoadjuvant, adjuvant and perioperative setting in advanced bladder cancer from ESMO 2018. They talk about the biology of the disease and considerations of available therapies, single vs combination, and for chemotherapy ineligible, as well as patients who opt out of chemothe...

Keynote-057 Trial for High-Risk Non-Muscle Invasive Bladder Cancer - Evan Yu

Details
(Length of Discussion: 7 min) Evan Yu and Alicia Morgans provide a review of bladder cancer prevalence and epidemiology in current clinical trials. This interview also includes the Keynote-057 trial results leading to plans for a phase 3 trial for a more efficacious treatment strategy for these patients with less toxicities. Biographies: Evan Yu, MD Alicia Morgans, MD, MPH Related Content: Pembrol...

Systemic Therapy Options for Renal Cell Carcinoma - Monty Pal

Details
(Length of Discussion: 14 min) Monty Pal and Charles Ryan discuss systemic therapeutic options and current clinical trials in the renal cell carcinoma space. Monty explains the clinical applications, considering appropriate patient selection and toxicity profile relevant in decision making. Biographies: Sumanta (Monty) Kumar Pal, MD Charles J. Ryan, MD Related Content: Cabozantinib Versus Sunitini...

A Nuclear Radiologist’s Perspective on Bone Targeted Therapies- Phillip Koo

Details
(Length of Discussion: 15 min) Phillip Koo shares with Charles Ryan his perspective on bone health from the view of the nuclear radiologist discussing proper imaging techniques leading to an accurate categorization of types of fractures; pathologic, either tumor-driven or insufficiency fractures vs post-traumatic. Closing comments lead to the clinical responsibilities to incorporate from the ERA 2...

Is There Still a Role for Chemotherapy in Bladder and Prostate Cancer - Maria De Santis

Details
(Length of discussion: 21 minutes) Maria De Santis and Alicia Morgans review the role of chemotherapy in genitourinary malignancies. This discussion evolves to appropriate patient selection, sharing clinical preference in dosing chemotherapy and their view of supportive care. Biographies: Maria De Santis is a medical oncologist and Chair of Section for Interdisciplinary Genito-Urinary Cancer Medic...

Immunotherapy in Bladder Cancer - Arjun Balar

Details
(Length of Discussion: 16 min) Arjun Balar and Alicia Morgans discuss outcomes in bladder cancer trials with a focus on primary endpoints, duration of response, and adverse events. Trials to practice with accurate clinical staging may lead to the ultimate goal of organ conservation in this patient population. Biographies: Arjun Balar, MD is the director of the genitourinary medical oncology progra...

Targeting Treatment to Subtypes in Prostate Cancer - Misha Beltran

Details
(Length of Discussion: 14 min) Misha Beltran and Alicia Morgans discuss treatment selection for patients with unique molecular subtypes. They discuss the use of ADT in this patient population as well as chemotherapy. Interestingly, they highlight the shared alteration and learnings from the study of small cell lung cancer. Biographies: Himisha Beltran, MD, Medical Oncologist, Dana Farber Cancer In...

The Use of Molecular Profile in Renal Cancer - Martin Voss

Details
(Length of Discussion: 10 min) Daniel George and Martin Voss discuss the evolving management of patients with advanced renal cell carcinoma with a focus on the genomic landscape in high risk localized disease. Based on molecular profiles, we may be able to prognosticate more accurately on their risk for recurrence. Applicability of this biomarker data will guide the future in appropriate therapeut...
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe